title: PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.
authors.affiliation: From the Departments of Neurology (E.M.M., J.C.M.), Epidemiology (E.M.M., J.C.M.), Pathology (J.C.M.), and Medicine (J.C.M.), Johns Hopkins University, Baltimore, MD.
authors.forename: Ellen M
authors.initials: EM
authors.lastname: Mowry
authors.affiliation: From the Departments of Neurology (E.M.M., J.C.M.), Epidemiology (E.M.M., J.C.M.), Pathology (J.C.M.), and Medicine (J.C.M.), Johns Hopkins University, Baltimore, MD. jm@jhmi.edu.
authors.forename: Justin C
authors.initials: JC
authors.lastname: McArthur
mesh_terms: D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D007577:JC Virus / Q000276:immunology; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced*; D009103:Multiple Sclerosis / Q000188:drug therapy; D000069442:Natalizumab / Q000009:adverse effects*
chemical_list: D007155:Immunologic Factors; D000069442:Natalizumab